Search results
Evolus (EOLS) Set to Announce Earnings on Tuesday
ETF DAILY NEWS· 2 days agoEvolus (NASDAQ:EOLS – Get Free Report) will be releasing its earnings data after the market closes on Tuesday, May 7th. Analysts expect Evolus to post earnings of ($0.07) per share for the quarter ...
Warren Buffett Stocks: What's Inside Berkshire Hathaway's Portfolio?
Investor's Business Daily· 6 hours agoTake Coca-Cola stock, which has grown dividends for more than 50 years in a row. Between 1965 and...
3 Biotech Stocks to Double Your Money in the Next 24 Months
InvestorPlace· 1 day agoThe biotechnology sector is renowned for its potential to deliver groundbreaking medical treatments...
Earnings call: Krystal Biotech sees strong Q1 growth, plans global expansion By Investing.com
Investing.com· 1 day agoKrystal Biotech Inc. (NASDAQ:KRYS) has announced robust financial results for the first quarter of...
Stocks Close Mixed; Disney Was Worst Stock On Dow
Investor's Business Daily· 5 hours agoBut investors focused on its 10% earnings drop over last year's quarter on flat sales. Analysts polled by FactSet..., the company announced it will buy...
3 Biotech Stocks to Buy and Hold Through 2030 and Beyond
Motley Fool via Yahoo Finance· 6 days agoWith a pipeline that carries several dozen programs, the company should deliver plenty of regulatory...
EyePoint Pharmaceuticals stock target cut, retains Buy rating By Investing.com
Investing.com· 14 hours agoThe reduction follows a significant 43% drop in EyePoint's share value on Monday, which contrasted...
When Will BRAIN Biotech AG (ETR:BNN) Breakeven?
Simply Wall St. via Yahoo Finance· 2 days agoAs path to profitability is the topic on BRAIN Biotech's investors mind, we've decided to gauge market sentiment. Below we will provide a high-level...
This Under-the-Radar Stock Is Up by 96% This Year: Time to Buy?
Motley Fool via Yahoo Finance· 3 days agoIn other words, the downside is massive, while the upside is limited. Investors should stay far away...
GlycoMimetics downgraded after Phase 3 trial fails to meet endpoint By Investing.com
Investing.com· 14 hours agoTuesday, H.C. Wainwright adjusted its stance on GlycoMimetics (NASDAQ:GLYC) stock, moving the ...
